breast cancer
Conditions
Interventions
Apply HairRepro MEDI Alpha to the scalp and eyebrows twice a day, 4 ml per application. A scalp cooling system (PAXMAN Scalp Cooling System) is applied to the head during chemotherapy, and cooling is
Sponsors
Department of Surgery and Science, Faculty of Medicine,Academic Assembly, University of Toyama
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Breast cancer patient 2) Patient who have been decided to receive preoperative or postoperative chemotherapy 3) ECOG PS of 0 to 2 4) Patients with sufficient preservation of major organ function 5) Age: 20 years or older 6) Category of consultation: outpatient 7) Patients who agreed to the use of Paxman at their own expense 8) Patients who have given written consent to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients with active multiple cancers 2) Patients with serious concomitant diseases (such as hepatic, renal, cardiac, hematological, or metabolic diseases) or psychiatric disorders 3) Patients who have been taking concomitantly banned drugs or study drugs within 4 weeks prior to the start of the study. 4) Patients with a history of allergy to Clozapine 5) Patients with eczema or other skin diseases on the head
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of improvement in alopecia 90 days after completion of chemotherapy based on imaging evaluation Percentage of hair loss based on imaging evaluation at each observation point | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's quality of life:Chemotherapy-Induced Alopecia Distress Scale Presence of adverse events Tolerability: Percentage of patients who completed all cycles of chemotherapy while using both drugs | — |
Countries
Japan
Contacts
Public ContactAraki Misato
University of Toyama Department of Surgery and Science Faculty of Medicine
Outcome results
None listed